Chest
ACCP/SCCM Consensus ConferenceDefinitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis
Section snippets
Sepsis
The systemic response to infection has been termed sepsis.1, 2 Sepsis is an increasingly common cause of morbidity and mortality, particularly in elderly, immunocompromised, and critically ill patients.1, 3, 4, 5 Sepsis has been reported to be the most common cause of death in the noncoronary intensive care unit.4, 6 Its rising incidence, new etiologies, and appearance in new populations of patients have been related to changing demographics and the increased use of more potent and
Multiple Organ Dysfunction Syndrome
The increasing incidence of morbidity and mortality caused by multiple organ failure has paralleled improvements in the life-support technologies available to patients admitted to an intensive care unit (ICU). As newer technologies for the monitoring and support of patients sustaining life-threatening critical illness became established, retrospective clinical studies found that a major threat to survival was not the underlying illness, or even a single complication thereof, but rather a
Severity-of-Illness Scoring System
A common theme in the two previous sections of this consensus statement is that we are treating more severely ill patients at later stages of illness. It is also apparent that many of these patients who have more complex illnesses may be suffering from a combination of chronic and acute disease. The nature of disease presentation is changing, and patient or host response is exemplified by the proposed introduction of new syndromes, such as SIRS and MODS. The recognition and treatment of these
Guidelines for the Use of Innovative Therapies in Severe Sepsis
Innovative therapy in severe sepsis usually involves an attempt to alter the systemic inflammatory response of a patient. Such forms of therapy are quite different from supportive therapy or therapies that are directed at the causative organism (eg, antibiotics or surgical procedures). Despite the use of these current therapies, the morbidity and mortality rates in severe sepsis remain high. Over the last 10 to 15 years, new antibiotics and increasingly sophisticated critical care have had
References (45)
- et al.
The septic syndrome: definition and clinical implications
Crit Care Clin
(1989) - et al.
Clinical predictors of the adult respiratory distress syndrome
Am J Surg
(1982) - et al.
Respiratory failure, hypotension, sepsis, and jaundice: a clinical syndrome associated with lethal hemorrhage from acute stress ulceration of the stomach
Am J Surg
(1969) Does drainage of intraabdominal pus reverse multiple organ failure?
Am J Surg
(1985)- et al.
Evidence for platelet-activating factor as a mediator of endotoxin-induced gastrointestinal damage in the rat: effects of three platelet-activating factor agonists
Gastroenterology
(1987) - et al.
The value of measuring severity of disease in clinical research on acutely ill patients
J Chronic Dis
(1984) - et al.
Evaluation of definition of sepsis
Chest
(1992) - et al.
A method for assessing the quality of a randomized control trial
Controlled Clin Trials
(1981) SCCM's New Horizons Conference on Sepsis and Septic Shock
Crit Care Med
(1985)Increase in national hospital discharge survey rates for septicemia: United States, 1979-1987
MMWR
(1990)
Septic shock: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy
Ann Intern Med
The influence of sepsis and multisystem organ failure on mortality in the surgical intensive care unit
Am Surg
Sepsis syndrome, the adult respiratory distress syndrome, and nosocomial pneumonia: a common clinical sequence
Clin Chest Med
A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock
N Engl J Med
Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis
N Engl J Med
Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin
N Engl J Med
A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis
JAMA
Sepsis syndrome: a valid clinical entity
Crit Care Med
Septicemia: the clinical diagnosis
J Antimicrob Chemother
“Sepsis”: clarity of existing terminology … or more confusion?
Crit Care Med
Microbial infection and the septic response in critical surgical illness
Arch Surg
Sepsis, the sepsis syndrome, multi-organ failure: a plea for comparable definitions
Ann Intern Med
Cited by (7898)
Systematic review and network meta-analysis of machine learning algorithms in sepsis prediction
2024, Expert Systems with ApplicationsParsimonious waveform-derived features consisting of pulse arrival time and heart rate variability predicts the onset of septic shock
2024, Biomedical Signal Processing and ControlAnalytical micro and nano technologies meet sepsis diagnosis
2024, TrAC - Trends in Analytical ChemistryA customised down-sampling machine learning approach for sepsis prediction
2024, International Journal of Medical Informatics
Manuscript received September 23; revision accepted January 22.
THE ACCP/SCCM CONSENSUS CONFERENCE COMMITTEE:
Conference Chairman:
Roger C. Bone M.D., F.C.C.P., Dean, Rush Medical College; Vice-President for Medical Affairs, Rush-Presbyterian-St. Luke's Medical Center, Chicago
Session Chairmen:
Robert A. Balk, M.D., F.C.C.P., Associate Professor of Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago
Frank B. Cerra, M.D., Professor of Surgery and Director of Critical Care, Department of Surgery, University of Minnesota Hospital, Minneapolis
R. Phillip Dellinger, M.D., F.C.C.P., Associate Professor and Director of Critical Care, Department of Medicine, Baylor College of Medicine, Dallas
Alan M. Fein, M.D., F.C.C.P., Director, Pulmonary and Critical Care Medicine Division, and Associate Professor of Medicine, SUNY Health Science Center, Winthrop-University Hospital, Mineola, NY
William A Knaus, M.D., Director, PCU Research Unit, George Washington University, Washington, DC
Roland M. H. Schein, M.D., Director of Critical Care Medicine and Associate Professor of Medicine, Department of Veterans Affairs Medical Center, University of Miami School of Medicine, Miami
William J. Sibbald, M.D., F.C.C.P., Chief, Program in Critical Care, and Professor of Medicine, University of Western Ontario, London, Ontario, Canada
Faculty:
Jerome H. Abrams, M.D., Assistant Professor of Surgery, University of Minnesota, Minneapolis
Gordon R. Bernard, M.D., F.C.C.P., Associate Professor of Medicine, Vanderbilt University Medical School, Nashville James W Biondi, M.D., Pulmonary and Critical Care Section, Yale University School of Medicine, New Haven
James E. Calvin, Jr., M.D., Associate Professor of Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago
Robert Demling, M.D., Professor of Surgery, Harvard Medical School, Boston
Patrick J. Fahey, M.D., F.C.C.P., Chief, Pulmonary and Critical Care, Loyola University Medical Center, Maywood, Ill
Charles J. Fisher, Jr., M.D., Associate Professor and Director, Center for Critical Care Research, Case Western Reserve University, Cleveland
Cory Franklin, M.D., Associate Professor of Medicine, University of Health Sciences/Chicago Medical School, North Chicago, Ill Kenneth J. Gorelick, M.D., Vice President, Medical and Regulatory Affairs, Genelabs Technologies, Inc, Redwood City, Calif
Mark A. Kelley, M.D., F.C.C.P., Vice Dean, Clinical Affairs, University of Pennsylvania Medical Center, Philadelphia
Dennis G. Maki, M.D., F.C.C.P., Professor of Medicine and Head, Section of Infectious Diseases; Attending Physician, Center for Trauma and Life Support, University of Wisconsin Medical School, Madison
John C. Marshall, M.D., Assistant Professor of Surgery, University of Toronto, and Toronto Hospital, Toronto
William W Merrill, M.D., Chief, Pulmonary Section, West Haven VA Medical Center, West Haven, Conn
John P. Pribble, Pharm. D., Assistant Director of Clinical Research, Synergen, Inc, Boulder, Colo
Eric C. Rackow, M.D., F.C.C.P., Professor and Chairman, Department of Medicine, St. Vincent's Hospital and Medical Center of New York, New York Medical College, New York Timothy C. Rodell, M.D., Vice President, Operations and Product Development, Cortech, Inc, Denver; Clinical Assistant Professor of Medicine, University of Colorado Health Sciences Center, Denver
John N. Sheagren, M.D., Chairman, Department of Internal Medicine, Illinois Masonic Medical Center; Professor of Medicine, University of Illinois College of Medicine, Chicago Michael Silver, M.D., F.C.C.P., Assistant Professor and Director, Respiratory Care Center, Rush-Presbyterian-St. Luke's Medical Center, Chicago
Charles L. Sprung, M.D., F.C.C.P., Director, Intensive Care Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel Richard C. Straube, M.D., Director, Infectious Diseases, Centocor, Inc, Malvern, Pa
Martin J. Tobin, M.D., F.C.C.P., Professor of Medicine, Loyola University of Chicago Stritch School of Medicine, Maywood, Ill Gordon M. Trenholme, M.D., Professor of Medicine, Rush Medical College, Chicago
Douglas Wagner, M.D., Senior Staff Scientist, ICU Research, George Washington University Medical Center, Washington, DC C. Douglas Webb, Ph.D., Director, Anti-Infectives, Roerig/Pfizer Pharmaceuticals, New York
Janice C. Wherry, M.D., Ph.D., Associate Director, Clinical Research, Cutter Biological, Miles, Inc, Berkeley, Calif
Herbert P. Wiedemann, M.D., Chairman, Department of Pulmonary and Critical Care Medicine, Cleveland Clinic Foundation, Cleveland
Cornelius H. Wortel, M.D., Adjunct Clinical Assistant Professor of Medicine, Critical Care/Emergency Medicine Section, Department of Medicine, Ben Taub General Hospital, Houston
Editors Note: The editorial on page 1481 and this report appear simultaneously in the June, 1992 issue of Critical Care Medicine (20: 724-26; 20: 864-74).